Quick Facts

• Primary Use: Addresses a variety of common fungal and yeast infections.
• Treats: Fungal infections of the skin (e.g., athlete’s foot, jock itch, ringworm).
• Also Addresses: Cutaneous candidiasis, which is caused by Candida species.

---

Miconazol acis is a topical preparation utilized to manage a range of common fungal skin infections and conditions caused by yeast. The application of this medication is indicated for addressing superficial skin infections such as athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis).

Additionally, Miconazol acis may be used for the localized management of cutaneous candidiasis (yeast infections of the skin) caused by an overgrowth of Candida species. These uses align with the accepted therapeutic application of miconazole-containing products for dermatological fungal conditions.

The medication is a component of a comprehensive treatment plan to support the improvement of symptoms associated with these fungal skin presentations, including redness, scaling, and itching. Continued use as recommended by a healthcare provider or package instructions is intended to resolve the fungal overgrowth.

Regulatory References

1. NIH MedlinePlus guidance on Miconazole

Official Eligibility Profile for Miconazol acis

The eligibility for using Miconazol acis is defined by specific regulatory criteria concerning age, known allergies, and physiological status, as stated in official prescribing information.

Classification	Population Rule
Absolute Contraindication	Contraindicated in patients with known hypersensitivity or allergy to miconazole/miconazole nitrate, other imidazole derivatives, or any of the product's excipients.
Use Restriction (Pediatric)	The topical cream must only be used in children under 2 years of age if specifically directed by a doctor. Safety and efficacy are generally not established for infants less than 4 weeks old.
Use Restriction (Geriatric)	Safety and effectiveness have not been evaluated in older adults aged 65 and over for some formulations, reflecting a lack of specific clinical data in this group.
Conditional Use (Reproductive)	Caution should be exercised when using the medicine during pregnancy and breastfeeding. Usage is generally advised only if the expected benefit outweighs potential risks.
Conditional Use (Comorbidity)	Patients concurrently taking oral anticoagulants (e.g., warfarin) must use the medication with caution and monitoring due to the potential for interaction. Safety is not established for some formulations in immunocompromised patients.

Interactions with other medicines and products

Miconazol acis (oral miconazole gel) carries a risk of interaction with numerous medicines due to its documented ability to inhibit the liver enzyme systems CYP3A4 and CYP2C9. This inhibition can significantly increase the concentration of co-administered drugs in the body, leading to a risk of heightened effects or toxicity.

Contraindicated Combinations

Official regulatory information mandates that Miconazol acis must not be used with certain medicines due to the potential for severe adverse reactions. This includes substances known to prolong the QT-interval (such as astemizole, cisapride, terfenadine, dofetilide, quinidine, mizolastine, sertindole, and pimozide), certain ergot alkaloids (e.g., ergotamine), and specific HMG-CoA reductase inhibitors (statins), namely simvastatin and lovastatin. The combination with triazolam and oral midazolam is also strictly restricted.

Clinically Significant Interactions

Category	Practical Regulatory Requirement
Oral Anticoagulants (e.g., warfarin)	Use of the over-the-counter formulation is contraindicated; for prescribed use, close monitoring of coagulation tests (e.g., INR) is mandatory to manage the risk of bleeding.
Oral Hypoglycaemics (e.g., sulphonylureas)	Requires careful monitoring, as co-administration can enhance the glucose-lowering effect, potentially leading to hypoglycaemia.
Other CYP Substrates	Caution and potential dose adjustment are required for many other drugs metabolized by CYP3A4/2C9, including certain immunosuppressants (e.g., cyclosporine) and calcium channel blockers.

Population-Specific Notes

The contraindication related to warfarin applies specifically to the non-prescription formulation. Furthermore, regulatory documents advise against use in patients with documented liver dysfunction.

Targeting the Fungal Cell Membrane

ightarrow Structural Disruption

Miconazole exerts its primary pharmacodynamic effect by interfering with the biosynthesis of ergosterol, an essential structural component of the fungal cell membrane. The drug acts as an inhibitor of the enzyme lanosterol 14alpha-demethylase (a cytochrome P450 enzyme), which is necessary for converting lanosterol into ergosterol. This targeted enzymatic inhibition prevents the formation of adequate ergosterol, while simultaneously causing the accumulation of toxic intermediate sterols. This mechanistic action restricts the availability of the membrane's stabilizing component, causing the fungal cell membrane to develop increased permeability and structural failure.

---

Inducing Intracellular Toxicity

ightarrow Oxidative Stress

The modification of the fungal cytochrome P450 system also initiates a secondary mechanism that leads to the excessive generation of Reactive Oxygen Species (ROS) within the fungal cell. This process results in a state of oxidative stress, causing widespread internal damage to vital cellular components, including DNA, proteins, and lipids. This cascade of toxicity complements the membrane damage, contributing to the overall destruction of the fungal organism (fungicidal activity).

How Miconazol acis is Used: Administration Guidelines

Miconazol acis is a medication intended for localized treatment, administered via specific topical (dermal) or intravaginal routes. The administration protocol is defined by the dosage form and the site of application.

Routes and Preparation

Route of Administration	Preparation Steps
Cutaneous (Topical)	The affected area must be cleaned and dried thoroughly before application. A thin layer should be applied and rubbed into the skin until fully penetrated.
Intravaginal	Suppositories or cream (using an applicator) are typically inserted at bedtime.

Standard Dosing and Duration

The following regimens reflect standard instructions:

• Topical Use: The cream or powder is typically applied twice daily (morning and night). For skin infections like athlete’s foot, treatment usually requires daily use for four weeks, while other tinea infections may require two weeks. Use must continue for at least one week after all signs of infection have disappeared.
• Vaginal Use: Regimens vary by strength, encompassing a one-day (1200 mg), three-day (200 mg), or seven-day (100 mg) course of suppositories or cream inserted once daily at bedtime.

Administration Rules

Instructions stipulate constraints regarding specific populations and use contexts:

• Pediatric Use: Topical forms are not for use in children under 2 years of age.
• Site Restriction: Topical cream and powder formulations are for external use only and are noted to be ineffective on the scalp or nails.
• Vaginal Constraints: Patients using the intravaginal forms are directed to avoid using tampons during the course of treatment.

Research Evidence / Overview of Studies for Miconazol acis

Evidence for Use in Tinea Infections (Athlete's Foot, Ringworm, and Jock Itch)

This section will summarize the structure of clinical evidence, including the Randomized Controlled Trials (RCTs) and Systematic Reviews, which monitored outcomes such as mycological and clinical cure for common fungal skin infections.

Research has examined patterns related to topical miconazole when studied in individuals with tinea infections. Studies typically used RCTs to compare the experience of patients receiving miconazole to those receiving an inactive treatment known as a placebo. Studies reported patterns in which the measured outcomes were generally different in groups receiving miconazole compared to groups receiving placebo treatments. This indicates that the research monitored changes in both the signs of infection and the laboratory status of the fungus during the defined time interval. Findings showed variability across different studies comparing miconazole against other antifungal treatments.

Evidence for Use in Cutaneous Candidiasis (Skin Yeast Infections)

This part will describe the types of studies, such as Controlled Trials, that exist for Miconazol acis when evaluated in Candida skin infections, outlining which patient outcomes and study populations were assessed in the research. The compound miconazole was studied for cutaneous candidiasis. Research monitored outcomes related to clinical and mycological assessments in miconazole groups, with variability observed compared to placebo groups. The overall evidence quality for this indication is categorized as moderate, and findings are often grouped with those of other similar antifungal compounds (azoles) in reviews.

Long-Term Studies and Durability of Outcomes

Research indicates that most of the available clinical evidence for topical miconazole is derived from studies with limited follow-up durations. The majority of trials monitored patient outcomes only for the specific time intervals required for the treatment course, often a few weeks. Limited information is available for long-term outcomes to adequately assess the risk of infection recurrence over periods like six months or one year. The research provides context but not individual predictions regarding the sustained absence of infection over extended periods.

What is Still Uncertain About Miconazol acis Research

The evidence highlights what is known—and what is still uncertain—about Miconazol acis. Key research limitation frames include the need for better long-term data, as follow-up durations were limited in most trials. Other significant uncertainties and gaps include limited information for long-term outcomes, and subgroup findings are uncertain due to limited evidence in certain populations, such as older adults and individuals with complex underlying health conditions. Furthermore, comparative evidence is lacking for certain head-to-head comparisons against all currently available antifungal agents, and the persistence of methodological weaknesses in many older trials continues to be noted in systematic reviews.

Common questions about Miconazol acis (FAQ)

---

Q: Can I use Miconazol acis if I am pregnant?

A: Regulatory documents state that it is generally recommended to avoid using Miconazol acis during the first trimester of pregnancy. For use during the second and third trimesters, studies have generally not shown an association with fetal harm. Regulatory sources state that use during pregnancy should be carefully considered, and the decision is typically made by a healthcare professional, weighing the potential benefits against any risks.

---

Q: Can Miconazol acis be used while breastfeeding?

A: According to the official product information, it is unknown if miconazole (the active ingredient in Miconazol acis) is secreted in amounts into breast milk that could affect an infant. Since the medication is poorly absorbed when applied topically or vaginally, it's not expected to cause significant side effects in a nursing child. Information regarding its use while breastfeeding should be obtained from a healthcare professional.

---

Q: What are common side effects of Miconazol acis?

A: As with many topical medications, the most common side effects reported for Miconazol acis are local skin reactions at the application site. These reactions can include mild burning, stinging, itching, or irritation of the skin. In the event of severe skin reactions, such as blistering or intense irritation, the official product information advises seeking consultation with a healthcare professional.

---

Q: Are there any medications that should not be taken with Miconazol acis?

A: Regulatory information indicates that Miconazol acis should not be used alongside certain other medicines, which are categorized as having 'major' interactions. Examples of drugs that are often not recommended for co-administration with miconazole include pimozide and certain types of ergotamine derivatives. These combinations are generally not recommended due to the potential for clinically significant risks.

---

Q: Can Miconazol acis increase the effect of blood thinners (anticoagulants)?

A: Official information confirms that miconazole, even when applied topically, can potentially enhance the effect of blood thinners (oral anticoagulants) like warfarin. This can lead to an increased risk of bleeding. The potential interaction means that close monitoring of blood clotting parameters by a healthcare professional may be necessary while using Miconazol acis.

How to Store and Dispose of Miconazol acis

Official regulatory guidelines mandate specific conditions for the storage and disposal of Miconazol acis products to ensure stability and safety.

Storage Requirements

Miconazol acis must generally be stored at or below 30, C, though some formulations, such as Miconazol acis Zinkpaste, require storage not exceeding 25, C. The product must not be refrigerated or frozen. Consistent with official labeling, the medicine must always be kept out of the sight and reach of children.

After the tube is first opened, Miconazol acis Cream and Zinkpaste must be used or discarded within 3 months.

Disposal Instructions

Disposal must strictly follow local requirements. The regulatory profile explicitly states that Miconazol acis must never be disposed of via wastewater (such as flushing down a toilet or pouring down a sink). Unused or expired product should be returned to a pharmacy or designated collection point in accordance with national pharmaceutical waste schemes.